Zepbound vs Wegovy: Which Is Right for You?

The fast answer

If you only have thirty seconds: Zepbound (tirzepatide) produced more weight loss than Wegovy (semaglutide) when the two were compared head-to-head in a large randomized trial — about 20% of body weight versus about 14% over 72 weeks¹. That makes Zepbound the stronger pick on pure scale-number results for most people. But "more" isn't automatically "right for you." Wegovy has a proven heart-disease benefit Zepbound hasn't yet matched in a trial⁴, the two carry the same GI side-effect profile, price and supply move constantly, and there are two mother-specific differences — birth control and pregnancy timing — that can flip the decision regardless of the efficacy gap. Here's the whole picture, fast. This guide is educational only and not medical advice.

Same class, two different molecules

Both drugs are weekly injections that quiet appetite and slow digestion, and both are FDA-approved for weight management. The difference is the molecule. Wegovy is semaglutide, which acts on one gut hormone pathway (GLP-1). Zepbound is tirzepatide, which acts on two (GLP-1 and GIP). That second target is the leading explanation for why tirzepatide tends to deliver more weight loss — you're pulling two levers instead of one. Same brand molecules power the diabetes versions you've heard of: semaglutide is also sold as Ozempic, and tirzepatide as Mounjaro.

Efficacy: the head-to-head settles the old argument

For years the comparison relied on separate trials, which is a shaky way to compare drugs. That's no longer necessary. SURMOUNT-5 randomized 751 adults with obesity (without diabetes) directly to Zepbound or Wegovy at their maximum tolerated doses for 72 weeks. Tirzepatide won cleanly: a mean 20.2% body-weight reduction versus 13.7% for semaglutide, with a bigger drop in waist circumference too, and more people hitting the 15%, 20%, and 25% loss thresholds¹.

Those numbers line up with each drug's own pivotal trial — semaglutide averaged about 15% in STEP 1², tirzepatide up to about 20% in SURMOUNT-1³ — so the direct comparison confirms what the separate studies hinted. If maximum weight loss is the goal, Zepbound is the evidence-backed pick. Just remember these are averages: plenty of people do beautifully on semaglutide, and the "best" drug is the one you tolerate and can actually stay on.

Side effects: effectively a tie

Don't pick based on side-effect fear — they're the same category for both. In every trial, the common complaints are gastrointestinal: nausea, diarrhea, constipation, and vomiting, mostly mild to moderate and concentrated during the dose-escalation weeks¹. The fix is the same for both drugs: titrate slowly, eat smaller and lower-fat meals, hydrate, and don't rush to the next dose if your body is still adjusting. Our GLP-1 side-effect quick-fix reference is the two-minute version to keep on your phone. Both drugs also carry a boxed warning about thyroid C-cell tumors seen in rodents and are not for people with a personal or family history of medullary thyroid carcinoma or MEN 2 — a conversation for your prescriber.

The mother-specific differences that can flip the decision

This is where a straight "which loses more weight" comparison stops being enough.

Birth control — a real Zepbound-only warning. Tirzepatide's own FDA label tells patients on oral hormonal contraceptives (the pill) to switch to a non-oral method or add a barrier method for 4 weeks after starting Zepbound and for 4 weeks after each dose increase, because slowed stomach emptying can reduce how well the pill is absorbed⁵. Semaglutide's label does not carry this instruction. If you rely on the pill and don't want to change methods, that difference alone may point you to Wegovy — or at least make a backup plan a must. Non-oral contraception (IUD, implant, patch, ring) isn't affected.

Pregnancy timing. Neither drug is used during pregnancy, but semaglutide has a notably long half-life, so its label advises discontinuing at least 2 months before a planned pregnancy⁶. If a baby might be on your horizon, that two-month runway is a real planning input — and a reason to raise family timing with your clinician before you start, whichever drug you choose.

Breastfeeding. There's no adequate safety data for either drug in breast milk, so both labels leave the nursing decision to you and your clinician rather than giving a green light. If you're currently nursing, that's a start-timing conversation, not a footnote.

Cost and access: the practical tiebreaker

On paper Zepbound wins efficacy, but the drug you can actually get and afford beats the one you can't. Both brands carry list prices well over a thousand dollars a month, and coverage for weight loss is inconsistent. Two things move the real decision:

• Insurance and supply. Whichever your plan covers — and whichever is in stock at your pharmacy this month — has a huge practical edge. Don't overthink a 6-point efficacy gap if only one is covered.
• Cash and compounded routes. Without coverage, many people start on a compounded version of one molecule through cash-pay telehealth, which is far cheaper than brand pens. We walk through the routes in how to get a GLP-1 without insurance and the pre-tax angle in GLP-1 cost without insurance: HSA/FSA and the real monthly math. Watch the pricing model, too: a flat, all-in monthly price usually beats a plan that climbs every time you titrate — see flat price vs dose-scaling.

One more edge for Wegovy: the heart data

If your history includes cardiovascular disease, the scales tip back. In the SELECT trial, semaglutide reduced the risk of major cardiovascular events (heart attack, stroke, cardiovascular death) in adults with overweight or obesity and established heart disease but without diabetes⁴. Tirzepatide has not yet reported an equivalent cardiovascular-outcomes result. For most people chasing weight loss this won't be the deciding factor, but if heart risk is part of your picture, it's a genuine point for Wegovy.

So which one?

• Chasing the most weight loss, no pill or pregnancy conflict? Zepbound has the head-to-head edge¹.
• On the pill and not switching methods, or planning a pregnancy soon? The Zepbound contraceptive warning and semaglutide's pregnancy-timing rule make Wegovy the cleaner conversation for some — talk it through with your prescriber⁵⁶.
• Heart disease in the picture? Wegovy has the proven cardiovascular benefit⁴.
• One is covered or in stock and the other isn't? Start the one you can actually get and stay on.

The honest truth is that the "best" GLP-1 is the one that fits your body, your budget, and your life stage — and that you can stay on, because stopping tends to reverse the results. That fit is exactly what our Rx-Readiness Score methodology weighs. It's also why a clinician-led, flat-priced option like CoreAge Rx — which can prescribe either molecule and adjust your dose and pace — sits at #1 on our ranking of GLP-1 providers for women, and why we sort the whole field by real value in cheapest GLP-1. Bring the birth-control and pregnancy questions to that first visit; they matter more than the six-point efficacy gap for a lot of mothers. Some links here earn us a referral fee, which never changes the ranking.